1. Home
  2. CRSP vs WAY Comparison

CRSP vs WAY Comparison

Compare CRSP & WAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • WAY
  • Stock Information
  • Founded
  • CRSP 2013
  • WAY 1999
  • Country
  • CRSP Switzerland
  • WAY United States
  • Employees
  • CRSP N/A
  • WAY N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • WAY
  • Sector
  • CRSP Health Care
  • WAY
  • Exchange
  • CRSP Nasdaq
  • WAY Nasdaq
  • Market Cap
  • CRSP 5.6B
  • WAY 6.7B
  • IPO Year
  • CRSP 2016
  • WAY 2024
  • Fundamental
  • Price
  • CRSP $71.48
  • WAY $38.00
  • Analyst Decision
  • CRSP Buy
  • WAY Strong Buy
  • Analyst Count
  • CRSP 18
  • WAY 13
  • Target Price
  • CRSP $72.59
  • WAY $44.92
  • AVG Volume (30 Days)
  • CRSP 2.6M
  • WAY 4.4M
  • Earning Date
  • CRSP 11-04-2025
  • WAY 11-05-2025
  • Dividend Yield
  • CRSP N/A
  • WAY N/A
  • EPS Growth
  • CRSP N/A
  • WAY N/A
  • EPS
  • CRSP N/A
  • WAY 0.48
  • Revenue
  • CRSP $38,050,000.00
  • WAY $1,011,303,000.00
  • Revenue This Year
  • CRSP N/A
  • WAY $11.39
  • Revenue Next Year
  • CRSP $388.50
  • WAY $10.18
  • P/E Ratio
  • CRSP N/A
  • WAY $78.49
  • Revenue Growth
  • CRSP N/A
  • WAY 17.14
  • 52 Week Low
  • CRSP $30.04
  • WAY $26.85
  • 52 Week High
  • CRSP $73.95
  • WAY $48.11
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 66.62
  • WAY 54.15
  • Support Level
  • CRSP $67.41
  • WAY $36.11
  • Resistance Level
  • CRSP $73.95
  • WAY $39.12
  • Average True Range (ATR)
  • CRSP 3.46
  • WAY 1.03
  • MACD
  • CRSP 0.87
  • WAY 0.02
  • Stochastic Oscillator
  • CRSP 76.46
  • WAY 59.61

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About WAY Waystar Holding Corp. Common Stock

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.

Share on Social Networks: